You are here: Welcome to the MPKB » Welcome to the MPKB » Health, food and drink » Aiming at Health » Health Maintenance and Olmesartan
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:food:aim_health:aging [02.24.2019] – [Recent studies showed] sallieqhome:food:aim_health:aging [03.13.2019] – [with additional studies] sallieq
Line 7: Line 7:
  
 ===== with additional studies ===== ===== with additional studies =====
 +
 +Clinical studies have demonstrated that some antihypertensive agents provide renoprotection independent of BP lowering.  (({{pubmed>long:16236804}})) 
  
  Although uncontrolled confounding might still exist, (//this was a short term study//) olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pubmed>long:24516110}}))   Although uncontrolled confounding might still exist, (//this was a short term study//) olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pubmed>long:24516110}})) 
Line 13: Line 15:
  
  Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued.  (({{pubmed>long:24772521}}))  Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued.  (({{pubmed>long:24772521}}))
 +
 +Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells.   (in breast cancer)(({{pubmed>long:    26138656}}))
  
 Data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed>long:27082551}}))  Data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed>long:27082551}})) 
Line 99: Line 103:
   * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed>long:23154587}}))    * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed>long:23154587}})) 
   * results suggest olmesartan can help decrease plasma AGE levels in patients on Hemodialysis (({{pubmed>long:22149003}}))    * results suggest olmesartan can help decrease plasma AGE levels in patients on Hemodialysis (({{pubmed>long:22149003}})) 
-  * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:3862195}})) +  * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:24384547}}))     
   * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects  (({{pubmed>long:24842388}}))    * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects  (({{pubmed>long:24842388}})) 
  
home/food/aim_health/aging.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.